Vertex doubles down on diabetes – acquires firm and resumes stem cell study
With the acquisition of Viacyte, a biotech firm focused on stem cell therapies to cure type 1 diabetes, Vertex hopes to accelerate development of its own candidate, which is moving forward following an FDA clinical hold.
by andreas lønstrup, translated by daniel pedersen
US-based Vertex Pharmaceuticals, a biotech firm developing a stem cell-derived candidate for the treatment of type 1 diabetes, is set to acquire a privately owned firm focused on the same area, Viacyte, a company press release reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Vertex has initial success in new diabetes project
For subscribers
Diamyd Medical meets study goal with diabetes vaccine
For subscribers
.jpg)
.jpg&w=384&q=75)
